Anti-Aging

Vesilute

Also known as: ED Dipeptide, Glu-Asp, L-Glutamyl-L-Aspartic Acid

Preclinical
Share:

Key Facts: Vesilute

Category
Anti-Aging
FDA Status
Not FDA Approved
Clinical Status
Preclinical - Limited human studies, available as supplement in some regions
Administration
Oral capsules
Typical Dose
1-2 capsules (10-20 mg) daily
Frequency
1-2x daily, before meals
Duration
30-day courses, repeat after 4-6 months
Also Known As
ED Dipeptide, Glu-Asp, L-Glutamyl-L-Aspartic Acid

Mechanism of Action

Vesilute is a dipeptide bioregulator that targets urogenital tissue. It is believed to normalize cellular function by reducing peptide deficiency and restoring protein synthesis inside cells. Research suggests it may enhance microcirculation within the prostate and support bladder function through epigenetic regulation of gene expression.

Research Summary

Part of Professor Khavinson's bioregulator research at the Saint Petersburg Institute of Bioregulation and Gerontology. Studies investigate potential role in supporting urinary tract and prostate health. Research suggests it may alleviate symptoms linked to bladder dysfunction and reduce prostate issues by improving local circulation. Limited published peer-reviewed data compared to other Khavinson peptides.

Trial Progress:Preclinical
Pre
I
II
III
IV
FDA

Dosing Information

Preclinical·Limited published research, primarily anecdotal

Typical Dosing

Community experience

Common Dose

1-2 capsules (10-20 mg) daily

Range

10-20 mg per day

Frequency

1-2x daily, before meals

Khavinson bioregulator for urogenital support. Often used in 30-day cycles. May be combined with Prostamax for prostate support in men. Limited Western research available.

Research Dosing

Scientific studies

Khavinson bioregulator dosing

Duration

30-day courses, repeat after 4-6 months

Administration

Oral capsules

Timing & Administration

Best Time to Take

Morning, before meals

1-2 times daily

Food Recommendation

With or without food

Why This Timing?

Bioregulator peptides typically taken morning on empty stomach for optimal absorption.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • Generally well-tolerated
  • Limited safety data in Western literature
  • Individual intolerance possible
  • Unknown long-term effects

References

Research This Peptide Further

Frequently Asked Questions

What does Vesilute do?

A synthetic dipeptide (Glu-Asp) bioregulator from the Khavinson peptide family, studied for urinary tract and prostate support. Research suggests it may help with bladder function and prostate microcirculation. Part of the tissue-specific bioregulatory compounds developed over 40+ years of research.

How does Vesilute work?

Vesilute is a dipeptide bioregulator that targets urogenital tissue. It is believed to normalize cellular function by reducing peptide deficiency and restoring protein synthesis inside cells. Research suggests it may enhance microcirculation within the prostate and support bladder function through epigenetic regulation of gene expression.

Is Vesilute FDA approved?

No, Vesilute is not currently FDA approved. Current status: Preclinical - Limited human studies, available as supplement in some regions

What are the side effects of Vesilute?

Reported side effects include: Generally well-tolerated, Limited safety data in Western literature, Individual intolerance possible, Unknown long-term effects. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Vesilute?

Community-reported common dose: 1-2 capsules (10-20 mg) daily (1-2x daily, before meals). Range: 10-20 mg per day. Administration: Oral capsules. Community-reported doses. Not FDA approved. Consult healthcare provider.

Related Peptides

Peptides commonly compared with Vesilute or used in similar applications.

Want updates on Vesilute research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.